CeaproTSXV: CZO

Ceapro announces 2006 third quarter financial results

· Issued by Ceapro via CNW
EDMONTON, Nov. 14 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
third quarter financial results for 2006. Ceapro produced solid financial
results with strong performance in sales and margins. Revenues for the third
quarter increased 17% to $762,000. Net earnings before interest, amortization,
taxes, and royalties increased to $24,000 from a loss of $3,000 in 2005. The
net loss for the quarter was $96,000 reduced 23% from $125,000 in 2005 with a
resulting in an income per share of $0.00.
Third quarter sales contributed to strong performance for the year to
date. Revenue from product sales rose 26% to $2.6 million resulting in income
from operations of $128,000, compared to an operating loss of $28,000 in the
first nine months of last year. Net earnings before interest, amortization,
taxes, and royalties increased 9% to $244,000. Foreign exchange losses and
research and product development expenses resulted in a net loss over the
first nine months. Gross margins remained strong at 58% of sales revenue,
primarily as a result of higher product sales, greater economies of scale, and
improvements in process efficiency.
"We are pleased to report that Ceapro continues to grow its business with
the best sales to date for a third quarter resulting in our best nine month
performance," said Dr. Mark Redmond, President and CEO of Ceapro. "We have
sold more active ingredients in each of the first three quarters than ever
before. This success comes from strong relationships with our partners and the
dedication and hard work of the Ceapro manufacturing team. We continue to
execute our business plan with initiatives focused on increasing our
production capacity, expanding markets, and developing new technologies to
open up new business opportunities for the future."

Third Quarter Highlights

<<
-   Revenues climbed 17% to $762,000
-   Sales of active ingredients up 12%
-   Net loss of $96,000 reduced from $125,000 in 2005
-   Working capital of $794,000
-   Gross margins of 56%
>>

Outlook

Our objective for the next 12 to 18 months is to further increase
revenues and utilize cash flow on a discretionary basis to enhance the scale
of operations. As a strategic focus, we continue to concentrate on increasing
sales and developing new opportunities, with emphasis placed on securing new
pharmaceutical and personal care customers to use our active ingredients and
launching our veterinary products in the United States. We are introducing
CeaProve(R) to North American corporations as part of corporate wellness
programs, and to healthcare providers internationally for point-of-care
diagnosis of diabetes and impaired glucose tolerance.
Ceapro advises that its 2006 third quarter report, which includes
management's discussion and analysis and unaudited financial statements is
being filed today with securities regulators and will be available on
www.sedar.com and on the Company's website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a growth stage biotechnology company. Ceapro's core
technology is the extraction of functional, active ingredients. We will
continue to add value to our extracts by manufacturing medical and therapeutic
products, support the use of our extracts in products for human and animal
health, and introduce health and wellness services employing our CeaProve(R)
diagnostic technology. Ceapro shares trade on the TSX Venture Exchange under
the symbol CZO. To learn more about Ceapro, visit our website at
www.ceapro.com. Shares Outstanding: 37,461,670, Recent Close: $0.30.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.


<<
CEAPRO INC.
Consolidated Balance Sheets


                                               September 30  December 31
                                                       2006         2005
                                                 (Unaudited)    (Audited)
-------------------------------------------------------------------------
ASSETS
CURRENT ASSETS
  Cash                                          $   413,880  $   438,045
  Accounts receivable                               432,192      982,347
  Inventories                                       171,451      228,158
  Prepaid expenses and deposits                     247,161       90,761
-------------------------------------------------------------------------

                                                  1,264,684    1,739,311

PROPERTY AND EQUIPMENT (NET OF
 ACCUMULATED AMORTIZATION)                          720,645      679,623
-------------------------------------------------------------------------

                                                $ 1,985,329  $ 2,418,934
-------------------------------------------------------------------------
-------------------------------------------------------------------------

LIABILITIES
CURRENT LIABILITIES
  Accounts payable and accrued liabilities      $   259,318  $   284,863
  Deferred revenue                                        0      229,676
  Callable debt                                      47,960       81,584
  Current portion of long-term debt                  26,560       33,519
  Currrent portion of royalties payable             136,658      106,508
-------------------------------------------------------------------------

                                                    470,496      736,150

DEFERRED ROYALTY REVENUE                            427,220      457,000
EMPLOYEE FUTURE BENEFITS OBLIGATION                 203,842      159,946
LONG-TERM DEBT                                      418,830      436,731
ROYALTIES PAYABLE                                   139,808      167,770
-------------------------------------------------------------------------

                                                  1,660,196    1,957,597
-------------------------------------------------------------------------

SHAREHOLDERS' EQUITY

SHARE CAPITAL                                     2,421,524    2,414,830
CONTRIBUTED SURPLUS                                 114,932      106,888
DEFICIT                                          (2,211,323)  (2,060,381)
-------------------------------------------------------------------------

                                                    325,133      461,337
-------------------------------------------------------------------------

                                                $ 1,985,329  $ 2,418,934
-------------------------------------------------------------------------
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Net (Loss) Income and Deficit
Unaudited

                          Nine Months Ended           Quarters Ended
                             September 30              September 30
                          2006         2005         2006         2005
----------------------------------------------- -------------------------

Revenue
  Sales               $ 2,606,565  $ 2,074,388  $   762,323  $   654,065
  Cost of goods sold    1,103,444      876,743      334,644      236,591
----------------------------------------------- -------------------------

  Gross margin          1,503,121    1,197,645      427,679      417,474
  Royalties, licenses,
   and product
   development fees             -       80,000            -            -
----------------------------------------------- -------------------------

                        1,503,121    1,277,645      427,679      417,474
----------------------------------------------- -------------------------

Expenses
  General and
   administration         726,511      728,329      214,124      206,164
  Royalties (net)         250,864      245,358       72,024       68,236
  Sales and marketing     253,668      174,261       99,387       54,675
  Amortization            108,892      119,667       36,930       40,847
  Interest on
   long-term debt          30,589       28,981       10,013       10,727
  Interest on callable
   debt and other           5,068        8,581        1,136        1,962
----------------------------------------------- -------------------------

                        1,375,592    1,305,177      433,614      382,611
----------------------------------------------- -------------------------

Income (loss) from
 operations               127,529      (27,532)      (5,935)      34,863
----------------------------------------------- -------------------------

Other income (expenses)
  Research and product
   development           (259,523)    (368,702)    (110,789)    (141,475)
  Other income
   (expenses)             (18,948)     216,682       20,496      (17,957)
----------------------------------------------- -------------------------

                         (278,471)    (152,020)     (90,293)    (159,432)
----------------------------------------------- -------------------------

Income (Loss) before
 income taxes            (150,942)    (179,552)     (96,228)    (124,569)

Income Taxes
  Current                 119,000      104,000       35,000       28,000
  Reduction as a
   result of applying
   non-capital losses
   carried forward
   against the current
   period's taxable
   income                (119,000)    (104,000)     (35,000)     (28,000)
----------------------------------------------- -------------------------

NET (LOSS) INCOME
 FOR THE PERIOD          (150,942)    (179,552)     (96,228)    (124,569)

Deficit, beginning
 of period             (2,060,381)  (2,003,374)  (2,115,095)  (2,058,357)
----------------------------------------------- -------------------------

Deficit, end of
 period               $(2,211,323) $(2,182,926) $(2,211,323) $(2,182,926)
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------

Net (loss) income
 per share:
  Basic               $     (0.00) $     (0.00) $     (0.00) $     (0.00)
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------
  Diluted             $     (0.00) $     (0.00) $     (0.00) $     (0.00)
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------



CEAPRO INC.
Consolidated Statements of Cash Flows
Unaudited
                           Nine Months Ended           Quarters Ended
                              September 30              September 30
                           2006         2005         2006         2005
----------------------------------------------- -------------------------

Operating Activities
  Net (loss) income
   for the period     $  (150,942) $  (179,552) $   (96,228) $  (124,569)
  Items not
   affecting cash
    Amortization          108,892      119,667       36,930       40,847
    Employee future
     benefits
     obligation            43,896       21,000       15,498       15,000
    Recognition of
     deferred royalty
     revenue              (29,780)           -       (8,710)           -
    Stock based
     compensation           9,113       49,945            -       48,147
----------------------------------------------- -------------------------

                          (18,821)      11,060      (52,510)     (20,575)

Changes in Non-Cash
 Working Capital Items
  Accounts receivable     550,155       49,238      271,425      295,769
  Inventories              56,707      113,796       18,201       38,796
  Prepaid expenses
   and deposits          (156,400)     (38,846)    (179,059)     (53,313)
  Accounts payable and
   accrued liabilities    (25,545)    (325,778)    (414,545)    (296,959)
  Deferred revenue       (229,676)     (80,000)           0            -
----------------------------------------------- -------------------------

                          176,420     (270,530)    (356,488)     (36,282)
----------------------------------------------- -------------------------

Investing Activities
  Purchase of property
   and equipment         (149,914)     (73,839)    (129,840)     (11,035)
  Restricted cash for
   the purchase of
   property and equipment       -       60,915            -       11,035
----------------------------------------------- -------------------------

                         (149,914)     (12,924)    (129,840)           -
----------------------------------------------- -------------------------

Financing Activities
  Repayment of
   long-term debt         (24,860)     (20,306)      (8,470)      (7,755)
  Repayment of
   callable debt          (33,624)     (29,929)     (11,424)     (10,163)
  Repayment of
   convertible debenture        -      (20,000)           -            -
  Proceeds from issuance
   of share capital             -      204,800            -            -
  Proceeds from exercise
   of stock options         5,625       89,861            -       80,361
  Increase (decrease)
   in royalties payable     2,188       81,779      (33,332)     (17,460)
----------------------------------------------- -------------------------

                          (50,671)     306,205      (53,226)      44,983
----------------------------------------------- -------------------------

Increase (decrease)
 in cash                  (24,165)      22,751     (539,554)       8,701
Cash at beginning
 of period                438,045       96,266      953,434      110,316
----------------------------------------------- -------------------------

Cash at end of period $   413,880  $   119,017  $   413,880   $  119,017
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------

Supplementary
 information:
  Interest paid       $    35,927  $    41,014  $    11,149   $   12,689
  Royalties paid      $   278,458  $   163,579  $   114,065   $   85,696
>>

%SEDAR: 00010110E

Ceapro on 6ix

Story so far

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases